Information Provided By: 
Fly News Breaks for May 31, 2019
ZYNE
May 31, 2019 | 07:13 EDT
H.C. Wainwright analyst Oren Livnat says that even with the stock up 324% year-to-date, shares of Zynerba Pharmaceuticals remain "potentially dramatically undervalued." The analyst continues to entirely value the company on the opportunity in Fragile X Syndrome, and he expects Zynerba to soon announce CONNECT-FX Phase 3 enrollment completion which would put the company on track for transformative topline data in Q4. He projects peak U.S. sales of $700M and keeps a Buy rating on the shares with a $23 price target.
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE
